Results 121 to 130 of about 40,312 (250)

Effectiveness of pharmacotherapy and behavioral interventions for smoking cessation in actual clinical practice

Therapeutic Advances in Respiratory Disease, 2009
Objectives: This study evaluated the effectiveness of behavioral interventions (brief counseling, nonspecific psychological support in groups — NSGS and cognitive behavioral group therapy — CBGT) in combination with bupropion SR for smoking cessation in ...
Nikoletta Rovina, Ioanna Nikoloutsou, Georgia Katsani, Efrossini Dima, Konstantinos Fransis, Charis Roussos, Christina Gratziou   +6 more
doaj   +1 more source

Smoking cessation and tobacco prevention in Indigenous populations [PDF]

This article systematically reviews 91 smoking cessation and tobacco prevention studies tailored for Indigenous populations around the world, with a particular focus on Aboriginal and Torres Strait Islander populations in Australia. We identified several
Adrian Esterman, Antony Veale, Brian Smith, Harshani Jayasinghe, Jeffrey Newchurch, Kristin Carson, Kuljit Singh, Malcolm Brinn, Matthew Peters, Thoracic Society of Australia and New Zealand   +9 more
core   +1 more source

Pilot Safety Evaluation of Varenicline for the Treatment of Methamphetamine Dependence. [PDF]

, 2009
Despite the worldwide extent of methamphetamine dependence, no medication has been shown to effectively treat afflicted individuals. One relatively unexplored approach is modulation of cholinergic system function.
Clement, Clayton, De La Garza, Richard, London, Edythe D, Miotto, Karen, Newton, Thomas F, Sevak, Rajkumar J, Shoptaw, Steven, Swanson, Aimee-Noelle, Zorick, Todd   +8 more
core  

Critical evaluation of real‐world evidence of repurposable medicines in the Alzheimer's disease drug development pipeline using a target trial emulation

Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 12, Issue 1, January/March 2026.
Abstract INTRODUCTION Repurposing Food and Drug Administration (FDA)‐approved drugs could accelerate treatment development for Alzheimer's disease (AD). METHODS Using the MarketScan claims database (2011 to 2020), we applied a trial emulation approach in two base cohorts: (1) individuals with mild cognitive impairment (MCI cohort) and (2) individuals ...
Reina Tonegawa‐Kuji, Ehud Karavani, Michael Danziger, Pengyue Zhang, Yuan Hou, Yadi Zhou, Marina Bykova, Andrew A. Pieper, Michal Rosen‐Zvi, Jeffrey Cummings, Feixiong Cheng   +10 more
wiley   +1 more source

<p>Promising Swellable Floating Bupropion Tablets: Formulation, in vitro/in vivo Evaluation and Comparative Pharmacokinetic Study in Human Volunteers</p>

, 2020
Mahmoud H. Teaima, Magdi M. Abdel Hamid, Nabil A. Shoman, Bhaskara Jasti, Mohamed A. El-Nabarawi   +4 more
openalex   +2 more sources

Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP‐1 Receptor Agonists in Inflammatory Bowel Disease

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 1, Page 17-39, January 2026.
GLP‐1 receptor agonists are generally effective in weight loss and improvement in metabolic markers. They are well tolerated in patients with inflammatory bowel disease, with observational evidence showing no increased risk of disease exacerbation and possible signals of reduced steroid use, hospitalization, and surgery. ABSTRACT Background Obesity and
Brooke Maracle, Steven Quan, Patrick Hamilton, Asma Shaikh, Deepan Hazra, Diane L. Lorenzetti, Stephanie L. Gold, Maitreyi Raman, Joëlle St‐Pierre   +8 more
wiley   +1 more source

Tobacco Cessation Treatments Among Young Adult Smokers [PDF]

, 2007
Summarizes a study of differences between younger and older adult smokers in their motivations and attempts to quit and their use of smoking cessation treatments.
Amy Sporer, Chioma Uzoigwe, Oksana Pugach, Richard Campbell, Sherry Emery, Susan Curry   +5 more
core  

The Novel CYP2A6 Inhibitor, DLCI-1, Decreases Nicotine Self-Administration in Mice. [PDF]

, 2020
During tobacco and e-cigarette use, nicotine is mainly metabolized in the human liver by cytochrome P450 2A6 (CYP2A6). Given that a slower CYP2A6 metabolism has been associated with less vulnerability to develop nicotine dependence, the current studies ...
Chen, Yen-Chu, Denton, Travis T, Fowler, Christie D, Fowler, James P, Lazarus, Philip, Sherafat, Yasmine, Staben, Andres, Wang, Jing, Watson, Christy JW   +8 more
core  

Efficacy and safety of European Medicines Agency (EMA)‐approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta‐analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 358-378, January 2026.
Abstract Aims We aimed at comparing different approved strategies (obesity management medications—OMM, endoscopic bariatric procedures—EBP, and metabolic bariatric surgery—MBS) with lifestyle intervention/placebo/no therapy (LSI/Pbo/NT) for the treatment of different BMI‐based classes of obesity (i.e., overweight—BMI: 25–29.9 kg/m2; class I—BMI: 30–34 ...
Rocco Barazzoni, Matteo Monami, Silvio Buscemi, Luca Busetto, Maurizio De Luca, Giuseppe Navarra, Benedetta Ragghianti, Giovanni Antonio Silverii, Amanda Belluzzi, Edoardo Mannucci, Paolo Sbraccia   +10 more
wiley   +1 more source

Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT‐5 trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 452-462, January 2026.
Abstract Aims In SURMOUNT‐5, tirzepatide led to greater body weight (BW) reduction versus semaglutide in adults with obesity without T2D. Health‐related quality of life (HRQoL) with tirzepatide versus semaglutide in SURMOUNT‐5 was evaluated. Materials and Methods This analysis included on‐treatment data from participants who received ≥1 dose of ...
Alpana P. Shukla, Julia P. Dunn, Elisa Gomez Valderas, Julia Fraseur Brumm, Chrisanthi A. Karanikas, Theresa Hunter Gibble   +5 more
wiley   +1 more source